Monthly Dosing of Atacicept in IgAN

Clinical trial NCT07020923 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07020923
Sponsor: Vera Therapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IgA Nephropathy (IgAN)Berger Disease

Start date: 2025-05-29
Primary completion: 2026-09-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.